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a b s t r a c t
Background: Health care workers (HCW) are among the highest risk groups for acquisition of COVID-19
because of occupational exposures. The WHIP COVID-19 Study aimed to evaluate the safety and eﬃcacy
of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population.
Methods: HCW, ﬁrst responders, and other occupationally high-risk participants were enrolled in a randomized, placebo-controlled clinical study of HCQ from April to October 2020. The trial compared daily
versus weekly HCQ with placebo and with a prospective cohort on HCQ for autoimmune diseases. Participants were followed for 8 weeks. Serology or a positive polymerase chain reaction test was used to
determine laboratory conﬁrmed clinical cases.
Results: A total of 624 participants were randomized to placebo (n = 200), weekly HCQ (n = 201), daily
HCQ (n = 197). For the primary safety end point, 279 (44.7%) participants experienced adverse event (AE)
level II or lower (total AEs n = 589), similar rates in all randomized groups (P = .188) with no hospitalizations or interventions required. Only 4 laboratory conﬁrmed COVID-19 cases occurred, with 2 in the
placebo arm and one in each HCQ randomized arm.
Conclusions: This randomized placebo-controlled trial was able to demonstrate the safety of HCQ outpatient chemoprophylaxis in high-risk groups against COVID-19. Future studies of chemoprophylaxis for
SARS-CoV-2 are needed as the epidemic continues worldwide.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Introduction
In December 2019, a novel disease caused by a new virus
now known as SARS-CoV-2, commonly referred to as COVID-19,
was identiﬁed in Wuhan, China (Huang et al, 2020). Since then,
this deadly pandemic infection has spread worldwide (with more
than 261 million cases and more than 5 million deaths as of
November 2021), with observed case-fatality ratios ranging between 0.9% to 7.9% (Johns Hopkins Coronavirus Resource Center,
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https://coronavirus.jhu.edu/map.html) (Johns Hopkins University of
Medicine, 2021).
HCW have a 3-fold increased risk of testing positive for COVID19 compared with the general population (Nguyen et al, 2020).
Disease prevention (pre-exposure [PrEP] or post-exposure [PEP])
prophylaxis and early treatment of other illnesses have been
demonstrated to prevent or diminish hospitalization rates and
avoid disease complications and multisystem-severe disease, and
are distinct from inpatient therapeutic management (Bariola et al,
2021, Dronavalli et al, 2020, Hiba et al, 2011, Taylor et al, 2021).
Transitioning from the current established procedure of clinical
management of COVID-19 from a hospital-based doctrine to a
community-based approach that involves outpatient chemoprophylaxis and early treatment will be a key means to prevent se-
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1201-9712/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license
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vere disease, avoid hospitalizations, and decrease COVID-associated
morbidity and mortality. Since 1969, HCQ (and chloroquine) has
been well documented to have in-vitro antiviral activity (Inglot,
1969). Antiviral activity against SARS-CoV and other viruses with
chloroquine was identiﬁed in 2004 and conﬁrmed in other invitro studies (Keyaerts et al, 2004, Sinha and Balayla, 2020). HCQ
changes the pH at the surface of the cell membrane, affects endocytosis, inhibits aspects of nucleic acid replication, and can interfere with the glycosylation of the ACE2 receptor. Additionally,
some viral proteins/enzymes can be affected by HCQ, which may
affect phosphorylation of p38 mitogen-activated protein kinase and
broadly impair virus assembly, restricting the new virus particle
transport, release, and other key processes (Perricone et al, 2020).
In Dengue virus models, HCQ activates the innate immune signaling pathways of interferon beta, activator protein 1, and nuclear
factor kappa B, and induces cellular production of reactive oxygen
species as host immune defense against viral infection (Wang et
al, 2015). Both HCQ and chloroquine (CQ) are capable of binding to
the human ACE-2 protein that serves as the CoV-2 viral receptor,
and interfere with the viral S protein’s ability to bind to gangliosides. Initial studies on SARS-CoV-2 showed improved HCQ activity
over CQ in-vitro with lower EC50 values for HCQ (Liu et al, 2020,
Wang et al, 2020).
Based on the available in-vitro and clinical data, HCQ was selected as chemoprophylaxis for persons at high risk for exposure
to infected populations through their work environment, including
HCW and persons employed in other high-risk occupations in our
study.

study enrollment, an invitation to participate in the study was extended. Participants were contacted directly to complete symptom
screening and informed consent process in person or electronically (consent process video and an online consent form). Verbal
consent was also available for those participants not comfortable
with the online process. A Data Safety Monitoring Board (DSMB)
was established and reviewed the study progress and safety data
monthly. The patient screening and allocation are detailed in the
Consort ﬂow diagram (Figure 1).
Study evaluations
Participants enrolled in the study were contacted by the study
staff to review study questionnaires and concomitant medications
and scheduled at their preferred participating clinical site for blood
draws, symptom review, and evaluation. All participants were evaluated and had laboratory evaluations done at baseline (postenrollment), week 4 and at week 8 of the study. Weekly symptom
assessments were completed via telephone and/or electronic encounters (virtual visits, e-mail), as preferred by the participant, to
enhance adherence to the protocol. The weekly monitoring was designed to assess for the development of any adverse events (AEs)
deﬁned as the following: COVID-19 related symptoms, COVID-19
clinical disease, and medication adverse effects. AE reporting used
the common terminology criteria for AEs, grades (1–5) and reporting based on US Department of Health and Human Services and
National Institutes of Health guidelines (HHS.gov; NIH.gov).
Participants who reported symptoms suggestive of COVID-19 infection (≥2 symptoms as listed in the updated Centers for Disease Control and Prevention list for April 27, 2020, which included
fever, cough, shortness of breath, chills, shaking chills, muscle pain,
headache, sore throat, and new loss of smell or taste) were referred for testing and evaluation by their primary care physician
or local medical center. Participants determined to be positive for
COVID-19 by either study or clinical testing completed the study at
that time point. Every effort was made to obtain conﬁrmatory test
results for COVID-19, including patient self-report, at study evaluations if presenting with symptoms, and from supportive medical records or study testing. Participants diagnosed with COVID-19
were asked to present for a study visit to provide a blood sample and answer an end of study questionnaire within 30 days of
recovery.
Samples were collected for SARS-CoV-2 serology assessments
using a SARS-CoV-2 IgG assay from Beckman Coulter, Inc, Indianapolis, Indiana, and conﬁrmed with the Elecsys Anti-SARS-CoV-2
assay from Roche Diagnostics, Rotkreuz, Switzerland. All tests were
completed following the manufacturer’s speciﬁcations and were
done in the HFH clinical laboratory or at the HFH Infectious Diseases Research Laboratory. Testing for COVID-19 serologies was not
completed in real time because the assays were not available at the
time of study initiation. Sample testing for serology was done in
batches, and the initial serologic testing was completed by November 2020.

Methods
Trial design
The study “Will Hydroxychloroquine Impede or Prevent COVID19” (WHIP COVID-19 Study) was designed as a 30 0 0-participant
study of HCW, ﬁrst responders and correctional/law oﬃcers (FR),
nursing home workers (NHW), medical students (MS), public transit workers, and household family members of HCW in Michigan
and Ohio. Eligible participants who were asymptomatic for prespeciﬁed signs and symptoms suggestive of COVID-19 infection
were entered into the study.
The study was a randomized, placebo-controlled, double blind
study with 3 active randomized arms and a comparator HCQ Cohort on maintenance full dose therapy for autoimmune disease
(AD). Participants were randomized in a 1:1:1 ratio to either oral
dosing of HCQ 400 mg weekly, HCQ 200 mg daily after a loading dose of 400 mg on day 1, or placebo daily. Only the unblinded pharmacist was aware of the randomized treatment assignment. Participants were provided 8-week packets of medications as per their randomization assignment. The nonrandomized
HCQ Cohort was followed for 8 weeks and underwent study procedures and remained on their medications. The trial protocol, statistical analysis plan, and the de-identiﬁed trial data have been uploaded to Vivli Center for Global Clinical Research Data repository
(https://doi.org/10.25934/0 0 0 07320).

Study outcomes

Patients and ethical statement

For the study primary outcome, clinical COVID-19 disease was
conﬁrmed in the participant at any time during the study if the
following was determined: (a) presentation with COVID-19 symptoms during study follow-up (deﬁned as fever ≥38° C, or ≥ nonfever symptoms that are new since baseline) and (b) laboratory
conﬁrmation of SARS-CoV-2 infection (test positive) deﬁned as at
least one positive laboratory test (reverse transcription–polymerase
chain reaction [RT-PCR] and/or IgM/IgG positive serology). The laboratory test results were obtained from (a) study blood samples

The study was approved by the Henry Ford Hospital (HFH) institutional review board on April 6, 2020, and the ﬁrst participant was enrolled on April 10, 2020. The protocol was submitted for an investigational new drug application and received FDA
approval (IND #149359), and was listed in ClinicalTrials.gov (N°
NCT04341441). All participants completed an online volunteer prescreening questionnaire form, and if the participant qualiﬁed for
168
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Figure 1. Consort ﬂow diagram.

(IgM and IgG serology) or (b) RT-PCR test results ordered by a participant’s primary care physician or local testing center or through
Employee Health.
Serology results were reviewed by 2 infectious disease specialists and adjudicated as negative, positive, or unknown/
indeterminate. Baseline positive serology was deﬁned as a participant having either a positive IgG, or positive IgM serology at baseline followed by IgG seroconversion at subsequent time points.

The trial had signiﬁcant declines in study enrollment following the US FDA revoke of the Emergency Use Authorization (EUA)
for hydroxychloroquine on June 15, 2020 (letter revoking EUA for
chloroquine phosphate and hydroxychloroquine sulfate, 6/15/
2020 [fda.gov]) (Food and Drug Administration, 2020). The EUA
was revoked following several published articles suggesting possible increased risk for morbidity and mortality, most of which were
subsequently retracted or disproven (Mehra et al, 2020, Raoult,
2020). The trial was affected by declining COVID-19 cases because of most of the enrollment occurring after the initial wave
of COVID-19 had declined in Michigan and the aggressive implementation of masking and safety measures in the hospital system
to prevent viral spread within our HCW population (Wang et al,
2021). The DSMB board met in November 2020 to evaluate the
clinical trial for safety and possibility of completion given the interim results and study enrollment. The DSMB determined the trial
study doses were safe, but because of low enrollment and low
event numbers, it was recommended to be stopped early because
the study end points would not be met. The WHIP COVID-19 Study
was terminated on December 14, 2020.

Statistical analyses
The study used intention to treat analysis to determine treatment eﬃcacy based on patients who were SARS-CoV-2 negative at
the baseline because the study did not have reliable assays available for COVID-19 detection at the time of initial enrollment. The
primary analysis compared the rate of COVID-19 disease for each
treatment group with that of the placebo group with a MantelHaenszel χ 2 test with multiplicity adjustment using the Dunnett
step up method. The stratifying variables were site, and high versus low-risk groups. The high-risk group included HCW (including
environmental service, NHW, and MS) who worked in COVID-19
care areas, emergency rooms (ER), and intensive care units caring for COVID-19 patients and household family members. Law
enforcement, FR, public transit drivers, and District Department
of Transportation bus drivers were also designated as a high-risk
group. Low-risk groups included HCW (including MS) who work in
non–COVID-19 patient-care areas without direct patient contact or
in administrative roles.
The sample size was determined with one planned interim
analysis when 50% of the participants had completed their 8 weeks
of treatment using an O’Brien-Fleming alpha spending method to
ensure an overall type 1 error of 0.05. With a sample size of 900
per group and alpha = 0.0492, the power to detect a 32% reduction
in COVID-19 disease rate (10% vs 6.8%) between the placebo group
and each HCQ treated group was determined to be 87%. Based
on the estimation of 5-10% of patients with SARS-CoV-2 infection
present at baseline, the study required 10 0 0 per group with a total
of 30 0 0 patients to complete the trial.
The DSMB and study chairs were provided weekly safety AE reports and convened monthly to review trial conduct and safety
data. All AEs were noted, including expected and unexpected
events reported by participants, and criteria for AE and severe AE
(SAE) used standard deﬁnitions.

Results
Study participants
All 624 enrolled participants were used for the safety analyses,
and 578 participants had suﬃcient data for the eﬃcacy analyses.
Of note, 200 participants were randomized to the placebo arm,
201 to the 400 mg HCQ weekly dose arm, and 197 to the 200 mg
HCQ daily dose arm, and 26 participants were enrolled who were
taking HCQ for their AD treatment in the nonrandomized control
arm. The participants were mostly female (59%), high-risk group
(69%), Caucasians (85%), with a mean age of 44.9 years. Most participants were working in health care, primarily hospitals (84%)
in the Detroit area, with the majority having direct patient contact (82%) and over half providing direct care to COVID-19 patients
(54%) (Table 1). Sixty percent reported contact with a COVID-19
positive patient before study entry.
Safety and adverse events
Of the 624 participants enrolled, only 279 (44.7%) experienced
an AE, with a total AEs reported during the study at 589 events.
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Table 1
Baseline Demographics
Variable

Response

Total (N=578)

Placebo (N=191)

400mg weekly (N=199)

200mg Daily (N=188)

Risk group

Lower Risk
High Risk
F
M
Mean (SD)
White
Black
AS/IN/PI
Unknown
Yes
No
Yes
No
Hospital System
First Responders
Skilled Nursing/Rehab Facility
Other
Yes
No
NA
Yes
No
NA

160 (28%)
418 (72%)
336 (58%)
242 (42%)
44.9 (11.9)
495 (86%)
24 (4%)
38 (7%)
21 (4%)
124 (22%)
449 (78%)
348 (60%)
228 (40%)
486 (84%)
9 (2%)
1 (0%)
82 (14%)
472 (82%)
98 (17%)
8 (1%)
315 (54%)
245 (42%)
18 (3%)

55 (29%)
136 (71%)
114 (60%)
77 (40%)
44.1 (12.7)
161 (84%)
9 (5%)
15 (8%)
6 (3%)
38 (20%)
150 (80%)
115 (60%)
76 (40%)
163 (86%)
4 (2%)
0 (0%)
23 (12%)
159 (83%)
30 (16%)
2 (1%)
105 (55%)
80 (42%)
6 (3%)

56 (8%)
143 (72%)
108 (54%)
91 (46%)
45.7 (11.6)
177 (89%)
5 (3%)
10 (5%)
7 (4%)
50 (25%)
148 (75%)
116 (59%)
81 (41%)
163 (83%)
3 (2%)
1 (0%)
29 (15%)
159 (80%)
35 (18%)
5 (3%)
101 (51%)
88 (44%)
10 (5%)

49 (26%)
139 (74%)
114 (61%)
74 (39%)
44.9 (11.4)
157 (84%)
10 (5%)
13 (7%)
8 (4%)
36 (19%)
151 (81%)
117 (62%)
71 (38%)
155 (83%)
2 (1%)
0 (0%)
30 (16%)
154 (82%)
33 (18%)
1 (1%)
109 (58%)
77 (41%)
2 (1%)

Gender
Age in years
Race

Recent history of travel
outside of Michigan?
Exposed to anyone diagnosed
with COVID19 conﬁrmed by
laboratory
Employment

Do you have direct contact
with patients?
Do you work in an area
categorized as direct COVID19 Care?

All study AEs were level 1 or 2 in severity. No AE grade 3 or 4,
or SAEs or visits to the ER or hospital occurred during the study
(Table 2).
Grade 1 and 2 AEs in participants were equally distributed between the randomized groups, with 85 participants in the placebo
arm, 95 in the weekly HCQ arm, and 97 in the daily HCQ arm
(P = .38). The patients on full dose HCQ only reported 2 participants with AEs. The severity of the events was similar per randomized group between grade 1 and 2 (P = .188).
The most common adverse effect reported was gastrointestinal
(GI) disorders (eg, nausea and gastrointestinal upset). GI symptoms
were similarly distributed between randomized treatment arms,
with 52 AEs in the placebo arm, and 42 in HCQ weekly and 54 in
the HCQ daily arm, respectively. Most AEs were grade 1. Similarly,
nervous system disorders (primarily headaches) were equally distributed between groups. Cardiac disorders were only palpitations,
mostly grade 1, without any patient requiring referral to the ER
or hospital. No statistically signiﬁcant differences in AEs distribution between groups were identiﬁed during the study at any time
point.

.27 to .85 for COVID-19 test positive results and .69 to 1.0 for conﬁrmed COVID-19 disease analyses.
Discussion
In our randomized, placebo-controlled trial for HCQ chemoprophylaxis using either daily or weekly dosing, we were able to
demonstrate the safety of the HCQ outpatient regimen compared
with placebo. No AEs grade 3 or 4 occurred during the study; no
patient required ER visits or hospitalization for adverse effects of
the medication, and most of the AEs documented in the study
follow-up of 624 patients were grade 1. This study clearly demonstrates the known safety proﬁle of HCQ, which is consistent with
numerous studies of rheumatologic use of daily HCQ chronically
for disease treatment (Fram et al, 2020). Unfortunately, despite
its established safety proﬁle since 1949, this long track record of
safety and tolerability was questioned based on retrospective chart
review studies with confounding patient populations in the early
phase of the pandemic, at a time when prompt testing was not
available and treatment was delayed, or other instances of misleading publications (Magagnoli et al, 2020, Mehra et al, 2020,
Rosenberg et al, 2020). The safety of outpatient HCQ has been
demonstrated in multiple previous studies in several different conditions, including the COVID-19 global pandemic (Observational
Health Data Sciences and Informatics (OHDSI), 2020, Perricone et
al, 2020). A major concern expressed by the FDA in revoking the
EUA approval for HCQ was the potential for cardiac arrhythmias
due to possible QTc prolongation. No patient in our study developed a cardiac arrhythmia and/or required medical evaluation for
cardiac symptoms. The COVID-19 cardiac and vascular endothelial
mechanisms of dysfunction are now better understood, and the associated risk for developing cardiac arrhythmias has been deemed
due to viral myocarditis (Douedi et al, 2021, Nabeh et al, 2021).
Myocarditis, cardiac arrhythmias, and cardiomyopathy are known
to be associated with QTc prolongation, and hence, early scientiﬁc
publications’ association of HCQ use with QTc prolongation in the
late inpatient and critical care setting may have suffered from lack
of early scientiﬁc understanding of the pathophysiology of COVID19 (Boehmer et al, 2021, Onohuean et al, 2021). This ﬁnding has
been supported by several other studies, including an Oxford study
that examined cardiac arrhythmia outcomes and obtained for its

Clinical COVID-19 cases
During the clinical trial, 35 participants were considered unknown/indeterminate for COVID-19 status because of serologies
not conﬁrming positive seroconversion, clinical symptoms without
a positive serology or PCR test, or missing laboratories or visits
to conﬁrm COVID-19 infection. All patients suspected of COVID-19
infection were referred to their Employee Health or primary care
providers for further evaluation and testing, and none required
hospitalization. Four patients were conﬁrmed positive by laboratory results (PCR or serology) during the study, with 3 participants
also demonstrating clinical disease, which was the study primary
end point (Table 3). The placebo arm had 2 patients with positive laboratory testing, with 1 with conﬁrmed disease. The two
randomized HCQ arms had one conﬁrmed positive COVID-19 case
each. No cases of COVID-19 or positive serologies were seen in the
25 patients who were chronically on HCQ. No statistically signiﬁcant difference was seen between groups for positive serologies or
conﬁrmed COVID-19 cases because of low event numbers (Table 4).
Multiple imputation analyses also demonstrated P values between
170
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random effects meta-analysis result, RR = 1.08, P value = .36 for
HCQ + azithromycin (AZ) use versus HCQ + amoxicillin use (another
broad-spectrum antibiotic), with the ﬁxed-effects meta-analysis
demonstrating a RR = 1.04, P value = .41. The study clearly demonstrated that cardiac arrhythmia AEs are not appreciably increased
by combining HCQ with AZ (Observational Health Data Sciences
and Informatics [OHDSI], 2020). HCQ was compared with sulfasalazine use, with no difference in cardiac arrhythmia risk for
HCQ, with a slightly lower RR = 0.89, P value = .13. Another review
of published cardiac complications attributed to HCQ in the pre–
COVID-19 era identiﬁed only 69 articles where most cardiotoxicity events were reversible with standard of care and only 2 fatalities were identiﬁed, and both were in acute intentional overdoses (Fram et al, 2020). Other concerns for hemolysis and methemoglobinemia with HCQ have not been reported in large clinical
prophylaxis trials.
More than 70 US and international studies and trials for HCQ
PrEP and PEP have been published since the initiation of this protocol (Monti et al, 2020). Boulware and colleagues published a trial
evaluating the beneﬁt of HCQ as a PEP regimen. The trial did not
demonstrate any signiﬁcant beneﬁt, but it was acknowledged that
there were ﬂaws with the design of the study and that further research was needed. This study also did not demonstrate any increases in cardiovascular or SAE or mortality in the HCQ treatment
arm (Lofgren et al, 2020). Other trials were done with randomized
samples, including studies by Skipper and colleagues, Rajasingham
and colleagues, and Mitja and colleagues (Boulware et al, 2020,
Mitjà et al, 2021, Rajasingham et al, 2021, Skipper et al, 2020). A
trial from Spain similar to our study demonstrated similar safety
ﬁndings and a trend toward HCQ beneﬁt in prevention of COVID19 in HCW but was unable to reach statistical signiﬁcance because
of diﬃculty in enrolling patients secondary to negative reports regarding HCQ therapy (Rojas-Serrano et al, 2021). Unfortunately, the
safety proﬁle of HCQ shown in multiple trials is not reﬂected in
the current guidelines from the WHO, which are based on only 6
studies solely from North America and Europe (World Health Organization, 2021). All these studies suffered from different limitations, including early termination, delayed intervention, underpowered sample sizes owing to missed accrual targets, and inability
to provide precise estimates of eﬃcacy of the HCQ strategy while
showing numerical beneﬁt for HCQ strategies. A recently published
trial by Seet and colleagues used a cluster randomization strategy
of 3037 men to evaluate several prophylaxis strategies in a wellcontrolled setting in Singapore. The study demonstrated absolute
risk reductions for laboratory conﬁrmed COVID-19 infection for
oral HCQ (21%, 2%–42%) and for povidone-iodine throat spray (23%,
7%–39%) over vitamin C control with a corrected alpha <0.0125
(Seet et al, 2021). In this large study, HCQ did not affect QTc interval in treated patients. Ivermectin and zinc did not show a beneﬁt in this study over vitamin C. Several meta-analyses have been
done to address these limitations, demonstrating eﬃcacy of HCQ
in the outpatient setting when evaluating the randomized clinical
trial data. Ladapo and colleagues, using ﬁxed-effects and randomeffects calculations, were able to show a 24% reduced outcome risk
for the composite outcome of COVID-19 infection, hospitalization,
and death (P = .025) for the HCQ intervention (Ladapo et al, 2020).
Similarly, a meta-analysis by Million and colleagues of 20 available
reports including 105,040 patients demonstrated that chloroquine
and its derivatives improve clinical and biological outcomes and reduce mortality by a factor of three in COVID-19 patients (Million et
al, 2020). In a recent Indian HCW retrospective PrEP cohort study
of 12,089 participants funded by the Indian Council of Medical Research, the use of HCQ prophylaxis was associated with declines
in COVID-19 positivity from 34% up to 72%, depending on the frequency of HCQ use in adjusted OR, with no difference in hospitalization rates (Badyal Dinesh et al, 2021). Dev and colleagues found

Note: No Serious Adverse Events were recorded in any of the treatment groups. No Grade 3 or 4 adverse events were recorded in any of the treatment groups. Top 10 reported adverse event groups are listed above. All other
AE disorders were less than 10 events total per group.

0
0
0
0
0
1
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
54
43
17
9
17
13
6
12
10
9
206
0
0
0
0
0
0
0
0
0
0
0
0
2
1
0
3
3
0
1
2
1
23
54
41
16
9
14
10
6
11
8
8
183
43
33
27
15
16
17
13
10
9
1
193
0
0
0
0
0
0
0
0
0
0
0
1
2
1
2
2
5
2
2
1
0
24
42
31
26
13
14
12
11
8
8
1
169
52
42
21
17
10
16
7
3
8
6
188
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
1
1
0
0
1
0
9
52
41
20
15
9
15
7
3
7
6
179
149
118
65
41
43
47
26
25
27
16
589
0
0
0
0
0
0
0
0
0
0
0
1
5
3
4
6
10
2
3
4
1
58
148
113
62
37
37
37
24
22
23
15
531
Gastrointestinal disorders
Nervous system disorders
Respiratory, thoracic and mediastinal disorders
General disorders and administration site conditions
Cardiac disorders
Musculoskeletal and connective tissue disorders
Psychiatric disorders
Skin and subcutaneous tissue disorders
Ear and labyrinth disorders
Eye disorders
All

2
1
3&4
2
1
3&4
2
1
1
3&4
2
1

Total

Grade
Adverse
Event

Table 2
Adverse Events by Treatment Arm

Treatment Group

All

Grade

Placebo

2

3&4

All

Grade

400mg HCQ weekly

All

Grade

200mg HCQ Daily

All

Grade

HCQ Cohort

3&4

All
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Table 3
COVID-19 Serology and Clinical Results
Treatment Group
Placebo

Covid Test∗

Covid
Disease∗ ∗

Unk/Ind†
Negative
Positive
Unk/Ind
Negative
Positive

400mg HCQ weekly

200mg HCQ Daily

Total

N

%

N

%

N

%

N

%

13
176
2
13
177
1

6.8
92.14
1.04
6.8
92.67
0.52

12
186
1
12
186
1

6.03
93.46
0.5
6.03
93.46
0.5

10
177
1
10
177
1

5.31
94.14
0.53
5.31
94.14
0.53

35
539
4
35
540
3

6.05
93.25
0.69
6.05
93.42
0.51

Note: ∗ p-value=0.699 for Covid Test positive; ∗ ∗ p-value=1.0 for Covid disease positive using Fisher exact test, on observed data assuming missing at random. † UNK/Ind refers to unknown/indeterminate serology/laboratory results for COVID-19 infection as some participants did not complete all laboratory assessments or the serological determination of COVID-19 could not be done due to inconclusive test results.
Table 4
COVID-19 Infections in participants will full laboratory data in both randomized and non-randomized groups.
COVID19
Diagnosis
Infection Status (test)∗
Clinical Disease∗ ∗

Treatment Group
Placebo

Negative
Positive
Positive

400mg HCQ weekly

200mg HCQ Daily

HCQ AD Therapy†

N

%

N

%

N

%

N

%

189
1
1

99
0.52
0.52

198
0
1

99.5
0
0.5

186
0
2

98.9
0
1.06

25
0
0

100
0
0

Note: ∗ Patients only testing positive for COVID-19 serology were included. ∗ ∗ Participants with both serology positive for
COVID-19 infection and clinical symptoms consistent with COVID-19 disease were included. P-value for the comparison between groups including the participants with † HCQ therapy for autoimmune diseases was 0.75.

that sanitation workers and technicians at the hospitals were at
higher risk for COVID-19 infection. This correlated with inappropriate use of PPE and lack of use of HCQ. In participants using
HCQ, the risk reduction was 26% (RR 0.74, P .003) in 260 participants on treatment versus 499 controls (Dev et al, 2021). A recent
HCQ treatment review using the Cochrane review manager identiﬁed 19 treatment trials out of 903 studies screened. The analyses
demonstrated signiﬁcant beneﬁts in both improved rates of virologic cure (OR = 2.08) and of radiological cure (OR = 3.89), but no
effect on mortality (aHR = 1.05) in the symptomatic treatment settings (Mittal et al, 2021).
The WHIP COVID-19 Study was not able to demonstrate eﬃcacy
of the HCQ strategy because only 4 conﬁrmed cases of COVID-19
were identiﬁed in the study, a key limitation to assess the strategy
eﬃcacy. The low event rate was due to previously mentioned concomitant factors that occurred during enrollment. Our study participants’ risk was signiﬁcantly decreased in part by very aggressive
masking and social distancing interventions initiated at our facilities early in the epidemic, impacting the positivity rate for COVID19 in the HFH System, from which over 60% of our participant pool
was derived. The interventions were considered to be highly effective (Wang et al, 2021). The pandemic rates also declined in the
state during the most active period of recruitment, and therefore,
the community exposure rates declined during the period of April
to October of 2020 (US Department of Health and Human Services,
2021). Participant acceptance of HCQ also declined with the withdrawal of the EUA approval.
However, the study was able to demonstrate conclusively that
no increased risk for AEs was seen between the HCQ treatment
arms as compared with placebo. Because of limitations with study
participants presenting in person to the research or hospital settings during the pandemic, the participants could not be followed
on site, and COVID-19 cases that may have been detected with
more active in-person follow-up and with real-time testing could
have been missed. All symptomatic patients were referred for testing and evaluation because of symptoms but infrequently followed
up for these assessments, whereas none required hospitalization.

Another limitation was lack of availability of accurate real-time assays to detect COVID-19 during the early period of the pandemic.
Both assay availability and resource allocation of the available tests
for clinical use prohibited potential real time testing of patients
and case identiﬁcation.
In summary, the WHIP COVID-19 Study was able to conﬁrm
that HCQ when administered in the outpatient setting for occupationally high-risk groups for COVID-19 infection is safe as either a
daily or weekly dose. Meta-analyses and international studies have
shown the value and safety of HCQ as a chemoprophylactic strategy. With the emergence of multiple SARS-CoV-2 variants and diminished effectiveness of currently available vaccines, chemoprophylaxis should be more fully evaluated as part of a comprehensive
strategy to identify effective and safe regimens and interventions
to be made available as new variants emerge and especially for
the vulnerable populations for whom vaccine antibody response
and protection will likely be weak or ineffective (McCullough et
al, 2020, Pegu et al, 2021, Singh et al, 2021, Tenforde et al, 2021,
Tregoning et al, 2021).
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